ArticleJournal of clinical microbiology2006
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy.Journal of clinical microbiology · 2015Pooled it
- Diutina cutanea sp. nov.-phylogenomic-based analysis of a novel clinically relevant ascomycetous yeast.Medical mycology · 2026Article
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Isolation, identification, and characterization of Candida species isolated from oral specimens of cancer patients and healthy individuals; a cohort study in Galle District, Sri Lanka.BMC oral health · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Article
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Article
- Genome Assemblies of Two Rare Opportunistic Yeast Pathogens:G3 (Bethesda, Md.) · 2019Article
- Prevalence ofIranian journal of microbiology · 2019Article
- Dual DNA Barcoding for the Molecular Identification of the Agents of Invasive Fungal Infections.Frontiers in microbiology · 2019Article
- Epidemiology of fungal infections in China.Frontiers of medicine · 2018Review
- Microbial diversity in two traditional bacterial douchi from Gansu province in northwest China using Illumina sequencing.PloS one · 2018Article
- Invasive Candidiasis in Brescia, Italy: Analysis of Species Distribution and Antifungal Susceptibilities During Seven Years.Mycopathologia · 2017Article
- High Virulence and Antifungal Resistance in Clinical Strains ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2016Article
- Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Intensive care medicine · 2014Review
- Three clustered cases of candidemia caused by Candida quercitrusa and mycological characteristics of this novel species.Journal of clinical microbiology · 2014Article
- Article
- Candiduria in children and susceptibility patterns of recovered Candida species to antifungal drugs in Ahvaz.Journal of nephropathology · 2013Article
- Molecular identification and antifungal susceptibility testing of clinical isolates of the Candida rugosa species complex and proposal of the new species Candida neorugosa.Journal of clinical microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida rugosa is a fungus that appears to be emerging as a cause of infection in some geographic regions. We utilized the extensive database of the ARTEMIS DISK Antifungal Surveillance Program to describe the geographic and temporal trends in the isolation of C. rugosa from clinical specimens and the in vitro susceptibilities of 452 isolates to fluconazole and voriconazole. C. rugosa accounted for 0.4% of 134,715 isolates of Candida, and the frequency of isolation increased from 0.03% to 0.4% over the 6.5-year study period (1997 to 2003). C. rugosa was most common in the Latin American region (2.7% versus 0.1 to 0.4%). Decreased susceptibility to fluconazole (40.5% susceptible) was observed in all geographic regions; however, isolates from Europe and North America were much more susceptible (97 to 100%) to voriconazole than those from other geographic regions (55.8 to 58.8%). C. rugosa was most often isolated from blood and urine in patients hospitalized at the Medical and Surgical inpatient services. Notably, bloodstream isolates were the least susceptible to both fluconazole and voriconazole. C. rugosa should be considered, along with the established pathogens Candida krusei and Candida glabrata, as a species of Candida with reduced susceptibility to the azole antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.